文献速递白血病

硼替佐米联合化疗治疗儿童复发/难治性急性淋巴细胞白血病

The combination of bortezomib with chemotherapy to treat relapsed/refractory acute lymphoblastic leukaemia of childhood.
PubMed 文献 · Br J Haematol · 2017-01-24

27例(72.9%)达完全缓解或血小板未完全恢复的完全缓解,14例微小残留病低于0.1%;2年总生存率31.3%,达微小残留病应答的完全缓解患者2年总生存率68.4%;3例(8.1%)死于感染。

要点

  • 27例(72.9%)达完全缓解或血小板未完全恢复的完全缓解,14例微小残留病低于0.1%。
  • B细胞前体与T细胞患者缓解率相近:73.3% vs 71%。
  • 2年总生存率31.3%,达微小残留病应答的完全缓解患者为68.4%。

核心结论

  • 硼替佐米联合化疗是儿童复发/难治性急性淋巴细胞白血病合适且有效的选择。

研究设计与样本

  • 评估硼替佐米联合化疗在30例B细胞前体急性淋巴细胞白血病和7例T细胞急性淋巴细胞白血病患儿中的疗效与安全性。
  • 硼替佐米按1.3 mg/m2/次静脉给药,于第1、4、8、11天使用。
  • 化疗药物与TACL试验相同,包括地塞米松、多柔比星、长春新碱和聚乙二醇门冬酰胺酶。

主要发现

  • 27例(72.9%)达完全缓解或血小板未完全恢复的完全缓解(CR/CRp)。
  • 14例微小残留病低于0.1%。
  • 30例B细胞前体患者中22例(73.3%)达CR/CRp,7例T细胞患者中5例(71%)达CR/CRp。
  • 2年总生存率为31.3%;达微小残留病应答的CR/CRp患者2年总生存率为68.4%。
  • 3例(8.1%)死于感染。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Achieving complete remission (CR) in childhood relapsed/refractory acute lymphoblastic leukaemia (ALL) is a difficult task. Bortezomib, a proteasome inhibitor, has in vitro activity against ALL blasts. A phase I-II trial, reported by the Therapeutic Advances in Childhood Leukaemia and Lymphoma (TACL) consortium, demonstrated that bortezomib with chemotherapy has acceptable toxicity and remarkable activity in patients with relapsed ALL failing 2-3 previous regimens. We evaluated bortezomib in combination with chemotherapy in 30 and 7 children with B-cell precursor (BCP) and T-cell ALL, respectively. Bortezomib (1·3 mg/m2 /dose) was administered intravenously on days 1, 4, 8, and 11. Chemotherapy agents were the same as those used in the TACL trial, consisting of dexamethasone, doxorubicin, vincristine and pegylated asparaginase. Three patients (8·1%) died due to infections. Twenty-seven patients (72·9%) achieved CR or CR with incomplete platelet recovery (CRp). Fourteen had minimal residual disease (MRD) lower than 0·1%. Twenty-two of 30 BCP-ALL patients (73·3%) and 5/7 patients (71%) with T-cell ALL achieved CR/CRp. The 2-year overall survival (OS) is 31·3%; CR/CRp patients with an MRD response had a remarkable 2-year OS of 68·4%. These data confirm that the combination of bortezomib with chemotherapy is a suitable/effective option for childhood relapsed/refractory ALL.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Bertaina A, Vinti L, Strocchio L, et al. The combination of bortezomib with chemotherapy to treat relapsed/refractory acute lymphoblastic leukaemia of childhood. Br J Haematol. 2017. PMID: 28116786. doi:10.1111/bjh.14505

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。